Uterine Fibroids Therapeutics - Pipeline Assessment and Market Forecasts to 2017

GlobalData, July 2011, Pages: 65

Uterine Fibroids Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, “Uterine Fibroids Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Uterine fibroids Therapeutics market. The report identifies the key trends shaping and driving the global Uterine fibroids Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Uterine fibroids Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Uterine fibroids Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Uterine fibroids Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Uterine fibroids Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Uterine fibroids Therapeutics therapeutics market.
- Analysis of key recent licensing and partnership agreements in Uterine fibroids Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Uterine fibroids Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Uterine fibroids Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Uterine fibroids Therapeutics market landscape? – Identify, understand and capitalize.

1
1

1.1 List of Tables
1.2 List of Figures
2 Uterine fibroids Therapeutics: Introduction
2.1 Disease Overview
2.2 Epidemiology
2.3 Etiology and Pathophysiology
2.4 Signs and Symptoms
2.5 Commonly Used Diagnosis Test
2.5.1 Pelvic Exam and Medical History
2.5.2 Ultrasound
2.5.3 Hysteroscopy
2.5.4 Laparoscopy
2.5.5 Magnetic Resonance Imaging
2.5.6 CT Scan
2.5.7 Hysterosalpingography
2.6 Treatment and Management Options
2.6.1 Watchful Waiting
2.6.2 Surgery
2.6.3 Drug Therapy
2.7 Pipeline Report Guidance
3 Uterine FibroidsTherapeutics: Market Characterization
3.1 Uterine Fibroids Therapeutics Market Size (2005-2010) – Global
3.2 Uterine Fibroids Therapeutics Market Forecast (2010-2017) – Global
3.3 Uterine Fibroids Therapeutics Market Size (2005-2010) – The US
3.4 Uterine Fibroids Therapeutics Market Forecast (2010-2017) – The US
3.5 Uterine Fibroids Therapeutics Market Size (2005-2010) – France
3.6 Uterine Fibroids Therapeutics Market Forecast (2010-2017) – France
3.7 Uterine Fibroids Therapeutics Market Size (2005-2010) – Germany
3.8 Uterine Fibroids Therapeutics Market Forecast (2010-2017) – Germany
3.9 Uterine Fibroids Therapeutics Market Size (2005-2010) – Italy
3.10 Uterine Fibroids Therapeutics Market Forecast (2010-2017) – Italy
3.11 Uterine Fibroids Therapeutics Market Size (2005-2010) – Spain
3.12 Uterine Fibroids Therapeutics Market Forecast (2010-2017) – Spain
3.13 Uterine Fibroids Therapeutics Market Size (2005-2010) – The UK
3.14 Uterine Fibroids Therapeutics Market Forecast (2010-2017) – The UK
3.15 Uterine Fibroids Therapeutics Market Size (2005-2010) – Japan
3.16 Uterine Fibroids Therapeutics Market Forecast (2010-2017) – Japan
3.17 Drivers and Barriers for the Uterine Fibroids Therapeutics Market
3.17.1 Drivers for the Uterine Fibroids Therapeutics Market
3.17.2 Barriers for the Uterine Fibroids Therapeutics Market
3.18 Opportunity and Unmet Need Analysis
3.19 Key Takeaway
4 Uterine fibroids Therapeutics: Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles of the Major Marketed Products in the Uterine Fibroids Therapeutics Market
4.3.1 Gonadotropin Releasing Hormone Agonists
4.3.2 Gonadotropin releasing hormone antagonists (Gn-Rha)
4.3.3 Androgens
4.3.4 Oral Contraceptive Pills
4.4 Key Takeaway
5 Uterine Fibroids Therapeutics: Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Uterine Fibroids Therapeutics Pipeline – Pipeline by Phases of Development
5.3.1 Uterine Fibroids Therapeutics – Phase III Pipeline
5.3.2 Uterine Fibroids Therapeutics – Phase II Pipeline
5.3.3 Uterine Fibroids Therapeutics – Phase I Pipeline
5.3.4 Technology Trends Analytic Framework
5.4 Uterine Fibroids Therapeutics Market – Clinical Pipeline by Mechanism of Action
5.5 Uterine Fibroids Therapeutics – Promising Drugs Under Clinical Development
5.6 Molecule Profile for Promising Drugs Under Clinical Development
5.6.1 Esmya (ulipristal acetate)
5.6.2 Vaginal Mifepristone
5.7 Other Key Molecules in the Pipeline
5.7.1 Proellex
5.7.2 Elagolix
5.8 Key Takeaway
6 Uterine Fibroids Therapeutics: Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Companies Participating in Uterine fibroids Therapeutics Clinical Trials
7 Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Uterine Fibroids Therapeutics: Implications for Future Market Competition
8 Uterine Fibroids Therapeutics: Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 PregLem SA
8.2.2 Repros Therapeutics Inc
8.2.3 Other Companies in the Uterine fibroids Therapeutics Market
9 Uterine Fibroids Therapeutics: Licensing and Partnership Deals
10 Uterine Fibroids Therapeutics: Appendix
10.1 Market Definitions
10.2 Abbreviation
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables
Table 1: Uterine Fibroids Therapeutics Market, Global, Revenue ($m), 2005–2010
Table 2: Uterine Fibroids Therapeutics Market, Global, Forecast ($m), 2010–2017
Table 3: Uterine Fibroids Therapeutics Market, The US, Revenue ($m), 2005–2010
Table 4: Uterine Fibroids Therapeutics Market, The US, Forecast ($m), 2010–2017
Table 5: Uterine Fibroids Therapeutics Market, France, Revenue ($m), 2005–2010
Table 6: Uterine Fibroids Therapeutics Market, France, Forecasts ($m), 2010–2017
Table 7: Uterine Fibroids Therapeutics Market, Germany, Revenue ($m), 2005–2010
Table 8: Uterine Fibroids Therapeutics Market, Germany, Forecasts ($m), 2010–2017
Table 9: Uterine Fibroids Therapeutics Market, Italy, Revenue ($m), 2005–2010
Table 10: Uterine Fibroids Therapeutics Market, Italy, Forecast ($m), 2010–2017
Table 11: Uterine Fibroids Therapeutics Market, Spain, Revenue ($m), 2005–2010
Table 12:Uterine Fibroids Therapeutics Market, Spain, Forecast ($m), 2010–2017
Table 13: Uterine Fibroids Therapeutics Market, The UK, Revenue ($m), 2005–2010
Table 14: Uterine Fibroids Therapeutics Market, The UK, Forecast ($m), 2010–2017
Table 15: Uterine Fibroids Therapeutics Market, Japan, Revenue ($m), 2005–2010
Table 16: Uterine Fibroids Therapeutics Market, Japan, Forecast ($m), 2010–2017
Table 17: Uterine Fibroids Therapeutics – Phase III Pipeline, 2010
Table 18: Uterine Fibroids Therapeutics – Phase II Pipeline, 2010
Table 19: Uterine Fibroids Therapeutics – Phase I Pipeline, 2010
Table 20: Uterine Fibroids Therapeutics – Most Promising Drugs Under Clinical Development, 2010
Table 21: Uterine Fibroids Therapeutics – Clinical Trials by Country, 2010
Table 22: Uterine Fibroids Therapeutics - Clinical Trials by Phase, 2010
Table 23: Uterine Fibroids Therapeutics - Clinical Trials by Status, 2010
Table 24: Uterine Fibroids Therapeutics - Prominent Sponsors, 2010
Table 25: Uterine Fibroids Therapeutics Market, Top Companies Participating in Therapeutics Clinical Trials, 2010
Table 26: Preglem SA. – Womens Health ,Pipeline,2010
Table 27: PregLem SA. - Deals
Table 28: Repros Pharmaceuticals –Women’s Health Pipeline, 2010
Table 29 : Repros Pharmaceuticals –Deals
Table 30: Uterine Fibroids Therapeutics Market – Future Players
Table 31: Uterine Fibroids Therapeutics, Global, Deals

1.2 List of Figures
Figure 1: Normal Uterus
Figure 2: Fibroid Uterus
Figure 3: Uterine Fibroids Therapeutics Market, Global, Revenue ($m), 2005–2010
Figure 4: Uterine Fibroids Therapeutics Market, Global, Forecast ($m), 2010–2017
Figure 5: Uterine Fibroids Therapeutics Market, The US, Revenue($m), 2005–2010
Figure 6: Uterine Fibroids Therapeutics Market, The US, Forecast ($m), 2010–2017
Figure 7: Uterine Fibroids Therapeutics Market, France, Revenue ($m), 2005–2010
Figure 8: Uterine Fibroids Therapeutics Market, France, Forecast ($m), 2010–2017
Figure 9: Uterine Fibroids Therapeutics Market, Germany, Revenue ($m), 2005–2010
Figure 10: Uterine Fibroids Therapeutics Market, Germany, Forecast ($m), 2010–2017
Figure 11: Uterine Fibroids Therapeutics Market, Italy, Revenue ($m), 2005–2010
Figure 12: Uterine Fibroids Therapeutics Market, Italy, Forecast ($m), 2010–2017
Figure 13: Uterine Fibroids Therapeutics Market, Spain, Revenue ($m), 2005–2010
Figure 14: Uterine Fibroids Therapeutics Market, Spain, Forecast ($m), 2010–2017
Figure 15: Uterine Fibroids Therapeutics Market, The UK, Revenue ($m), 2005–2010
Figure 16: Uterine Fibroids Therapeutics Market, The UK, Forecast ($m), 2010–2017
Figure 17: Uterine Fibroids Therapeutics Market, Japan, Revenue ($m), 2005–2010
Figure 18: Uterine Fibroids Therapeutics Market, Japan, Forecast ($m), 2010–2017
Figure 19: Opportunity and Unmet Need in the Uterine Fibroids Therapeutics Market
Figure 20: Uterine Fibroids Therapeutics – Strategic Competitor Assessment, 2010
Figure 21: Uterine Fibroids Therapeutics – Pipeline by Phases of Development, 2010
Figure 22: Uterine Fibroids Therapeutics – Technology Trends Analytics Framework, 2010
Figure 23: Uterine Fibroids Therapeutics – Technology Trends Analytics Framework – Description, 2010
Figure 24: Uterine Fibroids Therapeutics – Pipeline by Mechanism of Action, 2010
Figure 25: Uterine Fibroids Therapeutics – Clinical Trials by Country, 2010
Figure 26: Uterine Fibroids Therapeutics - Clinical Trials by Phase, 2010
Figure 27: Uterine Fibroids Therapeutics - Clinical Trials by Status, 2010
Figure 28: Uterine Fibroids Therapeutics - Overall Sponsors, 2010
Figure 29: Uterine Fibroids Therapeutics - Prominent Sponsors, 2010
Figure 30: Uterine Fibroids Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2010
Figure 31: Uterine Fibroids Therapeutics Market, Drivers and Restraints 2010
Figure 32: Implications for Future Market Competition in the Uterine Fibroids Market, 2010
Figure 33: Uterine Fibroids Therapeutics Market, Pipeline by Company, 2010
Figure 34: Market Forecasting Model

PregLem SA
Repros Therapeutics Inc

Customers who bought this item also bought

• Global Osteoporosis Therapeutics Market: Market Forecast, Patient Flow,Competitive Landscape, and Pipeline Analysis
• Disinfectants - Global Strategic Business Report
• Medical Nutrition - A Global Market Overview
• Overactive Bladder (OAB) Therapeutics - Global Strategic Business Report
• Diabetes Diagnostics - Global Strategic Business Report
• Molecular Diagnostics - Global Strategic Business Report
• Modern Management of Abnormal Uterine Bleeding
• Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014
• Cord Blood Stem Cells – A Global Market Overview
• Reconstructive and Reproductive Surgery in Gynecology